Entrada Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Entrada Therapeutics, Inc. (TRDA) on June 7, 2023, covering events occurring on June 7 and June 8, 2023. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Boston, MA.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance events.
Material Changes and Corporate Events
- Board Departure: Todd Foley resigned as a member of the Board of Directors effective June 7, 2023. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Annual Meeting Results: The 2023 Annual Meeting of Stockholders was held virtually on June 8, 2023. A quorum was established with 26,634,866 shares present or represented out of 33,187,199 outstanding shares.
- Director Elections: Stockholders elected Peter S. Kim, Ph.D., and Bernhardt Zeiher, M.D., as Class II directors to serve until the 2026 annual meeting.
- Accounting Firm Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Voting Results Detail
| Proposal | For | Against/Withheld | Abstain/Non-Votes |
|---|---|---|---|
| Election of Peter S. Kim, Ph.D. | 24,512,848 | 245,047 (Withheld) | 1,876,971 (Broker Non-Votes) |
| Election of Bernhardt Zeiher, M.D. | 24,696,429 | 61,466 (Withheld) | 1,876,971 (Broker Non-Votes) |
| Ratification of Ernst & Young LLP | 26,634,250 | 606 (Against) | 10 (Abstain) |
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. No specific risks or contingencies were disclosed in this report other than the standard disclosure regarding the resignation of a director.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following Todd Foley's resignation and the election of the new Class II directors.
- Confirm the continued engagement of Ernst & Young LLP as the independent auditor for the 2023 fiscal year.
- Review the definitive Proxy Statement filed on April 25, 2023, for detailed biographical information on the newly elected directors and further context on the governance matters.